December 11, 2019
1 min read
Save
GALILEO
Issue: December 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Bleeding events in patients assigned rivaroxaban (Xarelto, Janssen/Bayer) compared withan antiplatelet-based strategy after undergoing TAVR.